---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084282"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:40:54.988769+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma secures up to $250M loan at 8.25%; $200M funded to refinance existing debt

## Summary
- Tranche A of $200M funded on Feb 26, used to refinance $125M existing term loan and fund working capital.
- Loan bears fixed 8.25% interest quarterly; principal repayments start Q1 2030 in four equal quarterly installments.
- Second tranche of $50M available upon election by June 30, 2027, subject to conditions.
- No financial covenants; collateral includes substantially all assets including intellectual property.
- Loan matures 5 years from closing; prepayment subject to exit fee of 1% and makewhole within first year.

## SEC filing metadata
- accession: 0001193125-26-084282
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/0001193125-26-084282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/d59490d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084282
- JSON: https://secwatch.observer/filing/0001193125-26-084282.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084282.txt

## Source-grounded claims
- claim_id: 75fd5a3c847541c2d4b8475408f85cdb1edb1bd7
  claim: UroGen Pharma Ltd. incurred term loan of up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC at 8.25% per annum fixed maturing 5th year anniversary of the Tranche A Closing Date.
  evidence_excerpt: On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/0001193125-26-084282-index.htm
- claim_id: cc82681161e45eec4e881f7eb9c096f36dd80375
  claim: UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).
  evidence_excerpt: On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/0001193125-26-084282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.